[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pd-l1-gene-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pd-l1-gene-mutation":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100638493","programmed-cell-death-ligand-1-petct-in-various-pd-l1-related-disease-patients-100638493",false,"NCT07618936","Programmed Cell Death Ligand 1 PET\u002FCT in Various PD-L1-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PD-L1 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","ALL","18 Years","80 Years",{"count":19,"type":20},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-PD-L1 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various PD-L1-related disease patients",[25,26,27,28],"PD-L1 Gene Mutation","PD-L1 Gene Amplification","PD-L1-related Disease","Positron Emission Tomography",[30,31,32],"PET\u002FCT","PD-L1","DMP10","RECRUITING","2026-05-24",{"date":36,"type":37},"2026-06-01","ACTUAL",{"date":36,"type":20},{"date":40,"type":20},"2031-06-01",{"name":42,"class":43},"Tianjin Medical University","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100614423","trimpact-real-world-first-line-atezolizumab-use-in-stage-iv-nsclc-with-pd-l1-50-100614423","NCT07279402","TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%","TRIMPACT: A Prospective Real-World Study of Atezolizumab Monotherapy as First-Line (Stage IV) Treatment in Patients With Non-Small Cell Lung Cancer With PD-L1 Tumor Cell Expression ≥50% and No Targetable Mutations","Inclusion Criteria:\n\n* Signed informed consent form.\n* Diagnosis of stage IV non-small cell lung cancer.\n* Male or female patients aged 18 years or older.\n* Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye.\n* Patients who have received up to 3 cycles of atezolizumab at the screening visit.\n\nExclusion Criteria:\n\n* Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication.\n* Known or suspected hypersensitivity to atezolizumab.\n* Pregnant or breastfeeding women.",{"count":53,"type":20},150,"This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.",[56,25,57,58],"NSCLC Stage IV","Atezolizumab","Real World Study",[60],"NSCLC, PD-L1, Atezolizumab, Real World","2026-04-29",{"date":63,"type":37},"2026-04-30",{"date":65,"type":37},"2025-09-15",{"date":67,"type":20},"2027-10-01",{"name":69,"class":70},"Antalya Training and Research Hospital","OTHER_GOV",25,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100549168","clinical-efficacy-of-tumour-treatment-vaccine-ttv-combined-with-pd-1-in-the-treatment-of-relapsed-refractory-advanced-solid-tumours-100549168","NCT06430502","Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours","Inclusion Criteria:\n\n1. Male or female aged 18-75 years;\n2. Subjects must have histologically- or cytologically-confirmed diagnosis of advanced solid tumor(s) and have progressed on or is not eligible for available standard therapy;\n3. Subjects have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (non-nodal lesions with longest diameter ≥ 10 mm, or nodal lesions with short diameter ≥ 15 mm);\n4. ECOG score of 0-2, lifespan \\> 12 weeks;\n5. Women of childbearing age who have a negative pregnancy test within 7 days before treatment. Female patients of childbearing age, and male patients with partners of childbearing age must agree to use at least one medically recognized contraceptive method during study treatment and within at least 6 months after the last dose of investigational drug;\n6. Voluntarily participated in this study, signed the informed consent form, had good compliance, and cooperated with the follow-up.\n\nExclusion Criteria:\n\n1. The patient is diagnosed with central nervous system leukemia(symptoms, signs, imaging, cerebrospinal fluid);\n2. White blood cell count ≥ 50×10\\^9\u002F L or patients with rapid disease progression can't be guaranteed to complete a full treatment cycle;\n3. Patients with fungal, bacterial, viral or other uncontrollable infections or requiring four-level isolation treatment.\n4. HIV, HBV and HCV positive;\n5. Patients with diseases of the central nervous system or autoimmune central nervous system lesions, Including stroke, epilepsy, dementia;\n6. Patients have myocardial infection, cardiac angiography or stents, active angina or other obvious clinical symptoms, or have cardiopathic asthma or cardiovascular lymphocytic infiltrates，within 12 months;\n7. Patients are on anticoagulation or have severe coagulopathy (APTT\\>70);\n8. Patients in any condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 2weeks prior to investigational drug administration;\n9. Patients were infected with covid-19 within 2weeks prior to investigational drug administration;\n10. Subjects having any serious uncontrolled disease or in other conditions that would preclude them from receiving study treatment and are considered unsuitable for this study in the opinion of the investigator;\n11. Subjects in other conditions that are considered unsuitable for this study by the investigator.","85 Years",{"count":80,"type":20},200,"INTERVENTIONAL",[83],"NA","This study is intended to investigate the clinical efficacy of TTV vaccine combined with PD-1\u002FPD-L1 inhibitor in the treatment of relapsed and refractory advanced solid tumours from a clinical perspective.",[86,25],"Cancer","2024-05-21",{"date":89,"type":37},"2024-05-28",{"date":91,"type":37},"2024-05-07",{"date":93,"type":20},"2027-12-01",{"name":95,"class":43},"Wuxi People's Hospital",1]